SeaStar Medical to Share Q1 Financial Insights in May 2025
SeaStar Medical to Announce First Quarter Financial Results
Denver, May 7, 2025 — SeaStar Medical Holding Corporation (NASDAQ: ICU), a dynamic player in the healthcare sector, is gearing up to disclose its first quarter financial results. The announcement is scheduled for May 14, 2025, after the market closes, followed by a conference call and webcast to delve into the details of the financial performance and ongoing business advancements.
Details of the Financial Release
The event will commence at 4:30 p.m. ET, which falls at 2:30 p.m. MT. All interested parties are encouraged to attend as SeaStar Medical will share key insights regarding its financial status and strategic direction. The company is eager to engage with investors, providing them with a comprehensive understanding of its operations and performance metrics.
Webcast Information
To enhance accessibility, a live webcast will be available to the public during the announcement. For those unable to attend the live event, a replay will be made available shortly after the call concludes, ensuring that all stakeholders can stay informed on updates.
How to Join the Conference Call
For those wishing to participate in the conference call directly, dial-in numbers have been provided. In the U.S., participants can reach the call by dialing 1 (800) 715-9871, while international callers can connect using the number 1 (646) 307-1963. This opportunity provides a platform for listeners to engage directly with the management team.
SeaStar Medical's Focus and Innovations
SeaStar Medical is at the forefront of healthcare innovation, dedicated to transforming therapies for patients facing severe health challenges such as organ failure. The company’s flagship product, QUELIMMUNE (SCD-PED), received FDA approval, marking a significant milestone as it is the only such therapy for the treatment of life-threatening acute kidney injury (AKI) caused by sepsis in critically ill pediatric patients. This groundbreaking product highlights SeaStar’s commitment to improving patient outcomes.
Therapeutic Focus and Breakthrough Designations
The Selective Cytopheretic Device (SCD) therapy developed by SeaStar has garnered the attention of the FDA, receiving Breakthrough Device Designation for six critical therapeutic indications. This recognition not only circumvents some traditional regulatory hurdles but also promises superior reimbursement dynamics upon commercial launch, which is vital for the financial health of the company.
Upcoming Clinical Trials
Currently, the company is spearheading a pivotal trial involving its SCD therapy for adult patients suffering from AKI, particularly those in need of continuous renal replacement therapy—a group currently facing limited treatment options. This initiative aims to bring new hope to over 200,000 affected adults annually in the U.S., paving the way for advancements in critical healthcare.
Investor Relations and Contact Information
To learn more about SeaStar Medical and its innovations, stakeholders are encouraged to visit the company’s website. They can access detailed information regarding the financial results and future prospects directly on their platform, where they share regular updates and press releases.
Contact:
For inquiries, investors may reach out to SeaStar Investor Relations via email at IR@SeaStarMed.com.
Frequently Asked Questions
What date will SeaStar Medical report its financial results?
SeaStar Medical will report its financial results on May 14, 2025.
Where can I access the webcast of SeaStar Medical's financial results?
The webcast will be available on SeaStar Medical's official website during and after the financial results announcement.
What is QUELIMMUNE, and why is it significant?
QUELIMMUNE is SeaStar’s first commercial product approved for treating life-threatening acute kidney injury (AKI) in critically ill pediatric patients, making it a crucial advancement in healthcare.
How can investors participate in the conference call?
Investors can join the conference call by calling the provided dial-in numbers: 1 (800) 715-9871 for the U.S. and 1 (646) 307-1963 internationally.
What is the goal of SeaStar's ongoing clinical trials?
SeaStar's current clinical trials aim to evaluate the effectiveness of their SCD therapy in adult patients with AKI, which affects a significant number of individuals annually.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
